Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday surge of over 28%, reaching a price of 4.9 HKD, with a trading volume of 21.44 million HKD. The company reported a 40.6% year-on-year decline in revenue to 2.711 million HKD for the mid-year 2025, while the loss narrowed by 17.9% to approximately 110 million HKD, resulting in a loss per share of 0.27 HKD. The revenue decline was primarily attributed to a reduction in CDMO services [1][2]. Group 1 - Chuangsheng Group-B's mid-year 2025 revenue was 2.711 million HKD, a decrease of 40.6% year-on-year [1] - The company reported a loss of approximately 110 million HKD, which is a 17.9% improvement compared to the previous year [1] - The loss per share for the period was 0.27 HKD [1] Group 2 - Recent breakthroughs in research and clinical trials were highlighted, particularly the TST001 treatment for gastric cancer, which showed a median overall survival (mOS) of 20.4 months in a study involving 82 patients [1] - In a subgroup of 26 patients with high CLDN18.2 expression, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68% [1] - The company is set to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers following regulatory approval [2] Group 3 - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, yielding positive early results [2] - The company has also made early clinical progress with innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]
创胜集团-B拉升逾28% 中期净亏损同比收窄17.9% TST001研究数据首次亮相ASCO